Physician profile
Joy Tao
NPI 1992365696
$3,942.19
in general payments reported to CMS, 2019-2025
16 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.94 · 2020: $76.65 · 2021: $408 · 2022: $800 · 2023: $547 · 2024: $578 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,991.89 | 2020-2025 | Botox, Rinvoq, Skyrizi |
| Lilly USA, LLC | $314.33 | 2020-2025 | Taltz, Ebglyss |
| Genzyme Corporation | $235.83 | 2021-2023 | |
| Janssen Biotech, INC. | $187.42 | 2022-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.78 | 2023-2025 | Spevigo |
| Revance Therapeutics, INC. | $173.99 | 2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $171.57 | 2022-2025 | |
| Galderma Laboratories, L.P. | $153.98 | 2022-2025 | |
| Incyte Corporation | $145.51 | 2024-2025 | Opzelura |
| Ucb, INC. | $121.87 | 2022-2025 | Bimzelx |
| Almirall LLC | $102.53 | 2025 | Klisyri, Seysara |
| Arcutis Biotherapeutics, INC. | $57.68 | 2023-2025 | Zoryve |
| Pfizer INC. | $44.71 | 2025 | |
| Verrica Pharmaceuticals INC. | $29.80 | 2025 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $18.94 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $14.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Tao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.